Overview

* Rallybio ( RLYB ) reports Q3 net income of $16.0 mln, reversing a loss from last year

* Company generated $20 mln from sale of interest in REV102

* Cash runway extended through 2027, ensuring financial stability

Outlook

* Rallybio ( RLYB ) expects to report RLYB116 study data in 4Q 2025

* Company's cash runway extended through 2027

* Rallybio ( RLYB ) evaluating future development of RLYB332

Result Drivers

* REV102 SALE - Co generated $20 mln from sale of interest in REV102, boosting financial results

* COST MANAGEMENT - Decrease in R&D expenses due to reduced development costs and workforce reduction, offset by increased spending on RLYB116

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net $16.02

Income mln

Q3 -$6.93

Income mln

From

Operatio

ns

Q3 $7.14

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Rallybio Corp ( RLYB ) is $1.00, about 37.5% above its November 5 closing price of $0.63

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)